Skip to main content

Table 1 Patient characteristics of persistent PSA patient final cohort stratified by the two radiotherapy fractionation schedules (N = 69)

From: Comparison of hypofractionation and standard fractionation for post-prostatectomy salvage radiotherapy in patients with persistent PSA: single institution experience

 

Persistent PSA salvage radiotherapy cohort (N = 69)

CFR group

66 Gy in 33 fractions

(N = 36)

HFR group 52.5 Gy in 20 fractions

(N = 33)

p-value

Age, yr, median (IQR)

63

(59–68)

63

(55–68)

64

(59–68)

0.90

Follow-up post RT, Months, median (IQR)

59 (49–74)

59 (50–73)

64 (46–76)

0.98

First post- prostatectomy PSA, ng/mL

Median (IQR)

0.33 (0.16–1.57)

0.3 (0.14–1.5)

0.36 (0.2–2.4)

0.16

PreRT PSA, ng/mL, median (IQR)

0.56 (0.30–1.83)

0.55 (0.29–1.71)

0.60 (0.33–2.39)

0.25

PreRT PSA, ng/mL, range

0.1–30.0

0.12–12.5

0.10–30.0

 

ADT during RT, N (%)

47 (68)

29 (81)

18 (55)

0.02

Bicalutamide 150 mg, N (%)

23 (49)

16 (55)

7 (39)

 

LHRH agonist, N (%)

24 (51)

13 (45)

11 (61)

 

Duration of ADT,

Months, median (IQR)

24 (6–27)

24 (6–30)

24 (21–27)

0.04

Final pathology

Grade Group (GG), N (%)

   

0.021

 GG 1

3 (4)

3 (8)

/

 

 GG 2

27 (39)

11 (30)

166 (48)

 

 GG 3

21 (30)

13 (36)

8 (24)

 

 GG 4

8 (11)

6 (16)

2 (6)

 

 GG 5

10 (16)

3 (10)

7 (22)

 

pT stage, N (%)

   

0.08

 T1–T2a

7 (10)

6 (16)

1 (3)

 

 T2b–T2c

22 (32)

13 (36)

9 (27)

 

 T3–T4

40 (58)

17 (19)

23 (70)

 

SVI, N (%)

33 (48)

12 (33)

11 (33)

1.0

Positive SM, N (%)

28 (41)

14 (39)

14 (42)

0.77

ECE, N (%)

32 (46)

13 (36)

19 (58)

0.08

  1. CFR conventionally fractionated radiotherapy, HFR hypofractionated radiotherapy, IQR interquartile range, RT radiotherapy, PSA prostate-specific antigen, ADT androgen deprivation therapy, LHRH Luteinizing hormone-releasing hormone, SVI seminal vesicle invasion, SM surgical margins, ECE extracapsular extension